[go: up one dir, main page]

MX2017007299A - Composiciones en suspension de liberacion prolongada gastroretentivas. - Google Patents

Composiciones en suspension de liberacion prolongada gastroretentivas.

Info

Publication number
MX2017007299A
MX2017007299A MX2017007299A MX2017007299A MX2017007299A MX 2017007299 A MX2017007299 A MX 2017007299A MX 2017007299 A MX2017007299 A MX 2017007299A MX 2017007299 A MX2017007299 A MX 2017007299A MX 2017007299 A MX2017007299 A MX 2017007299A
Authority
MX
Mexico
Prior art keywords
extended release
release suspension
suspension compositions
gastroretentive extended
gastroretentive
Prior art date
Application number
MX2017007299A
Other languages
English (en)
Inventor
Kumar Ashish
Barat Singh Romi
P Jain Paras
Kaushik Suchitra
Kumar Vinay
Original Assignee
Sun Pharmaceutical Ind Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharmaceutical Ind Ltd filed Critical Sun Pharmaceutical Ind Ltd
Publication of MX2017007299A publication Critical patent/MX2017007299A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

La presente invención se relaciona a una composición en suspensión de liberación prolongada gastroretentiva, en donde la composición se caracteriza por no tener cambio sustancial en el perfil de liberación de disolución in-vitro en almacenamiento durante por lo menos siete días. La invención también se relaciona a procesos para la preparación de las composiciones en suspensión de liberación prolongada gastroretentivas.
MX2017007299A 2014-12-05 2015-05-01 Composiciones en suspension de liberacion prolongada gastroretentivas. MX2017007299A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN3553DE2014 2014-12-05
PCT/IB2015/053208 WO2016087952A1 (en) 2014-12-05 2015-05-01 Gastroretentive extended release suspension compositions

Publications (1)

Publication Number Publication Date
MX2017007299A true MX2017007299A (es) 2017-08-25

Family

ID=56091086

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017007299A MX2017007299A (es) 2014-12-05 2015-05-01 Composiciones en suspension de liberacion prolongada gastroretentivas.

Country Status (10)

Country Link
US (1) US20180008539A1 (es)
EP (1) EP3226839A4 (es)
JP (1) JP2017536404A (es)
AU (1) AU2015356781A1 (es)
BR (1) BR112017011922A2 (es)
CA (1) CA2969820A1 (es)
MA (1) MA41124A (es)
MX (1) MX2017007299A (es)
RU (1) RU2017123366A (es)
WO (1) WO2016087952A1 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX391660B (es) 2010-03-24 2025-03-21 Jazz Pharmaceuticals Inc Formas de dosis de liberacion controlada para substancias de farmaco de alta dosis, solubles en agua e higroscopicas
US10398662B1 (en) 2015-02-18 2019-09-03 Jazz Pharma Ireland Limited GHB formulation and method for its manufacture
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
CN109922801B (zh) 2016-09-09 2023-07-18 库蒂斯制药公司 甲硝唑和巴氯芬的混悬剂和稀释剂
US20180263936A1 (en) 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
WO2019126216A1 (en) * 2017-12-18 2019-06-27 Tris Phama, Inc. Pharmaceutical compositions comprising a floating interpenetrating polymer network forming system
US11337920B2 (en) 2017-12-18 2022-05-24 Tris Pharma, Inc. Pharmaceutical composition comprising GHB gastro-retentive raft forming systems having trigger pulse drug release
CA3085941A1 (en) 2017-12-18 2019-06-27 Tris Pharma, Inc. Ghb pharmaceutical compositions comprising a floating interpenetrating polymer network forming system
EP3740189A1 (en) 2017-12-18 2020-11-25 Tris Pharma, Inc. Modified release drug powder composition comprising gastro-retentive raft forming systems having trigger pulse drug release
JP7273976B2 (ja) * 2018-09-21 2023-05-15 アムニール コンプレックス プロダクツ リサーチ エルエルシー トリヘキシフェニジルを含む徐放性組成物
KR20200053746A (ko) 2018-11-09 2020-05-19 (주)아모레퍼시픽 졸-겔 조성물
JP7472116B2 (ja) 2018-11-19 2024-04-22 ジャズ ファーマシューティカルズ アイルランド リミテッド 耐アルコール性製剤
US20220062305A1 (en) * 2018-12-18 2022-03-03 DDP Specialty Electronic Materials US, Inc. Sustained release composition comprising an ethylcellulose
WO2020131780A1 (en) * 2018-12-18 2020-06-25 Ddp Specialty Electronics Materials Us, Inc. A sustained release composition comprising a methylcellulose
CN113473980A (zh) 2019-03-01 2021-10-01 弗拉梅尔爱尔兰有限公司 在进食状态下具有改善的药代动力学的γ-羟基丁酸酯组合物
CA3139217A1 (en) 2019-05-14 2020-11-19 Clexio Biosciences Ltd. Treatment of nocturnal symptoms and morning akinesia in subjects with parkinson's disease
US11654124B2 (en) 2019-07-29 2023-05-23 Amneal Pharmaceuticals Llc Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives
US10792262B1 (en) * 2019-07-29 2020-10-06 Saol International Limited Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives
TW202139986A (zh) 2020-02-21 2021-11-01 愛爾蘭商爵士製藥愛爾蘭有限責任公司 治療原發性嗜睡症之方法
CN112516159B (zh) * 2020-12-03 2022-06-17 爱希（北京）国际咨询有限公司 一种含有硝酸盐的组合物、胃漂浮剂及制备方法和应用
CN117042629A (zh) * 2021-01-13 2023-11-10 杜邦营养美国公司 胃滞留药物递送系统
US11154505B1 (en) 2021-02-03 2021-10-26 Kashiv Specialty Pharmaceuticals, Llc Extended release compositions comprising trihexyphenidyl
WO2022195476A1 (en) 2021-03-15 2022-09-22 Clexio Biosciences Ltd. Gastroretentive devices for assessment of intragastric conditions
CN112933055B (zh) * 2021-03-23 2023-01-13 安徽九华华源药业有限公司 帕利哌酮胃滞留片及其制备方法
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
CN117398380A (zh) * 2022-06-29 2024-01-16 威智医药股份有限公司 卡维地洛或其盐、组合物的新用途及该组合物和制备方法
WO2024030936A1 (en) * 2022-08-02 2024-02-08 Nutrition & Biosciences Usa 1, Llc Modified-release alginate-based composition
AU2023420299A1 (en) 2022-12-29 2025-07-10 Renata Pharmaceuticals (Ireland) Limited Pharmaceutical suspension of nilotinib
KR20250148613A (ko) 2023-02-03 2025-10-14 트리스 파마 인코포레이티드 저 나트륨 옥시베이트 밤마다 1회 투여 조성물
CN119074761B (zh) * 2024-09-10 2025-07-22 常州市儿童医院(常州市第六人民医院) 一种含铝碳酸镁和海藻多糖的制剂及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5273760A (en) * 1991-12-24 1993-12-28 Euroceltigue, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
AU1881600A (en) * 1998-12-23 2000-07-31 Alza Corporation Dosage forms comprising porous particles
JP2004002320A (ja) * 2002-03-04 2004-01-08 Medorekkusu:Kk 生体内で相転移する液状マトリックスおよび液状経口製剤
EP1492511B3 (fr) * 2002-04-09 2012-05-02 Flamel Technologies Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s)
US20050207983A1 (en) * 2004-03-05 2005-09-22 Pulmatrix, Inc. Formulations decreasing particle exhalation
CN101160126A (zh) * 2005-04-20 2008-04-09 默克公司 血管紧张肽ⅱ受体拮抗剂
EP2144599B1 (en) * 2007-03-02 2010-08-04 Farnam Companies, Inc. Sustained release pellets comprising wax-like material
WO2008122993A1 (en) * 2007-04-09 2008-10-16 Panacea Biotec Limited Controlled release formulation of coated microparticles
ES2397746T3 (es) * 2007-04-11 2013-03-11 Biomarin Pharmaceutical Inc. Métodos de administración de tetrahidrobiopterina, composiciones asociadas y métodos de medición
WO2010011466A2 (en) * 2008-06-27 2010-01-28 Otonomy, Inc. Controlled-release cns modulating compositions and methods for the treatment of otic disorders
WO2011107855A2 (en) * 2010-03-04 2011-09-09 Torrent Pharmaceuticals Limited Sustained release oral liquid suspension dosage form
EP3137060B2 (en) * 2014-05-01 2023-12-20 Sun Pharmaceutical Industries Ltd Extended release suspension compositions

Also Published As

Publication number Publication date
WO2016087952A1 (en) 2016-06-09
AU2015356781A1 (en) 2017-06-29
RU2017123366A (ru) 2019-01-10
MA41124A (fr) 2017-10-10
EP3226839A4 (en) 2018-07-11
EP3226839A1 (en) 2017-10-11
BR112017011922A2 (pt) 2018-01-16
CA2969820A1 (en) 2016-06-09
RU2017123366A3 (es) 2019-01-10
US20180008539A1 (en) 2018-01-11
JP2017536404A (ja) 2017-12-07

Similar Documents

Publication Publication Date Title
MX2017007299A (es) Composiciones en suspension de liberacion prolongada gastroretentivas.
SA519401180B1 (ar) مركبات بيروليزين بها استبدال واستخداماتها
PH12019550235A1 (en) Kinase inhibitors and uses thereof
PH12017501956A1 (en) Compositions of obeticholic acid and methods of use
CL2017002650A1 (es) Compuestos novedosos
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
MX2016016143A (es) Compuestos de [1,2,4]triazol sustituido.
PH12018500071A1 (en) Plinabulin compositions
MX388170B (es) Polimorfos de selinexor
MX2021011906A (es) Composiciones de liberacion retardada de linaclotida.
MX2017014035A (es) Formas solidas novedosas.
PH12016501807A1 (en) Novel compounds
TN2017000179A1 (en) Synthesis of copanlisib and its dihydrochloride salt
MX2014005510A (es) Nuevas composiciones, produccion de las mismas y uso de las mismas para la produccion de poliamidas coladas.
MX2017003301A (es) Producto refractario, relleno para fabricar el producto, procedimiento para fabricar el producto y uso del producto refractario.
ES2421956A1 (es) Nueva forma cristalina de sulfato de sitagliptina
MX2017005891A (es) Sintesis de copanlisib y su sal diclorhidrato.
MX2018016290A (es) Agente antidesgaste.
MX2017003550A (es) Uso de cisteamina en tratamiento de infecciones causadas por levaduras/mohos.
MY181656A (en) Glue composition
IN2014CH00840A (es)
BR112016023767A2 (pt) forma sólida, composição farmacêutica, compostos, métodos, composições e utilizações
IN2014CH00304A (es)
MX2016015624A (es) Proceso para la preparacion de derivados de tiazol.